Currently submitted to: JMIR Dermatology
Date Submitted: Mar 14, 2026
Open Peer Review Period: Mar 24, 2026 - May 19, 2026
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Medication-Based Severity Stratification in Psoriasis Using Electronic Health Records
ABSTRACT
Background:
Psoriasis severity is commonly assessed using the Psoriasis Area and Severity Index (PASI), but PASI scores are frequently unavailable in real-world data due to inconsistent documentation and is often affected by interobserver variability. Medication-based proxies may offer a pragmatic alternative for severity stratification in registry-based research.
Objective:
This study aimed to develop a medication-based severity scale for psoriasis and evaluate its association with PASI scores in Danish real-world registry and electronic health record (EHR) data.
Methods:
We conducted a retrospective registry-based study including individuals with an ICD-10 diagnosis of psoriasis in Eastern Denmark between 2006 and 2016. Data were obtained from the Danish National Patient Registry, the Danish National Prescription Registry, and a population-wide EHR repository. PASI scores were extracted from unstructured clinical notes using regular expressions. Anti-psoriatic medications were categorized into mild, moderate, and severe groups based on Danish treatment guidelines. Correlations between PASI scores and the medication severity scale were analyzed.
Results:
Among 19218 individuals with psoriasis, 18848 had relevant prescriptions and 2884 had PASI scores. The automated PASI extraction algorithm demonstrated high performance (F1 score 0.98). A weak but statistically significant correlation was observed between PASI scores and the medication severity scale (r = 0.057, P = .001), indicating partial overlap between clinical severity and prescriptions. Moderate and severe therapies were generally associated with higher PASI values, though exceptions reflected treatment history and healthcare system structure.
Conclusions:
Automated extraction of PASI scores from EHR data is feasible and reliable in large-scale registry research. The modest association between PASI and medication-based severity highlights differences between clinical severity measures and real-world prescribing practices. Medication-based stratification may therefore serve as a complementary proxy for disease severity in registry-based studies when PASI scores are unavailable.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.